AstraZeneca PLC (AZN)
161.59
-0.88
(-0.54%)
USD |
NYSE |
Sep 02, 16:00
161.99
+0.40
(+0.25%)
After-Hours: 18:50
AstraZeneca Research and Development Expense (TTM) : 14.21B for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 14.21B |
| December 31, 2025 | 13.84B |
| September 30, 2025 | 13.65B |
| June 30, 2025 | 13.19B |
| March 31, 2025 | 12.57B |
| December 31, 2024 | 12.18B |
| September 30, 2024 | 11.56B |
| June 30, 2024 | 10.98B |
| March 31, 2024 | 10.67B |
| December 31, 2023 | 10.27B |
| September 30, 2023 | 9.889B |
| June 30, 2023 | 9.764B |
| March 31, 2023 | 9.631B |
| December 31, 2022 | 9.527B |
| September 30, 2022 | 9.412B |
| June 30, 2022 | 9.203B |
| March 31, 2022 | 8.567B |
| December 31, 2021 | 8.007B |
| September 30, 2021 | 7.299B |
| June 30, 2021 | 6.627B |
| March 31, 2021 | 6.209B |
| December 31, 2020 | 5.949B |
| September 30, 2020 | 5.736B |
| June 30, 2020 | 5.583B |
| March 31, 2020 | 5.525B |
| Date | Value |
|---|---|
| December 31, 2019 | 5.38B |
| September 30, 2019 | 5.899B |
| June 30, 2019 | 5.813B |
| March 31, 2019 | 5.818B |
| December 31, 2018 | 5.846B |
| September 30, 2018 | 5.360B |
| June 30, 2018 | 5.487B |
| March 31, 2018 | 5.467B |
| December 31, 2017 | 5.556B |
| September 30, 2017 | 5.54B |
| June 30, 2017 | 5.533B |
| March 31, 2017 | 5.604B |
| December 31, 2016 | 5.683B |
| September 30, 2016 | 5.840B |
| June 30, 2016 | 5.850B |
| March 31, 2016 | 5.873B |
| December 31, 2015 | 5.739B |
| September 30, 2015 | 5.466B |
| June 30, 2015 | 5.425B |
| March 31, 2015 | 5.250B |
| December 31, 2014 | 5.076B |
| September 30, 2014 | 4.920B |
| June 30, 2014 | 4.385B |
| March 31, 2014 | 4.343B |
| December 31, 2013 | 4.172B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| GSK Plc | 9.289B |
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Novo Nordisk A/S | 8.086B |